KDR and neoplasm: Since VEGFR2 is not only expressed in the tumor vasculature but has also been identified on the surface of a variety of tumors (4, 10, 11), V21-DOS47 targets both VEGFR2+ vascular endothelial cells and VEGFR2+ tumor cells.